SUMMARY
The natural product withaferin A (WFA) exhibits antitumor and antiangiogenesis activity in vivo, which results from this drug's potent growth inhibitory activities. Here, we show that WFA binds to the intermediate filament (IF) protein, vimentin, by covalently modifying its cysteine residue, which is present in the highly conserved a-helical coiled coil 2B domain. WFA induces vimentin filaments to aggregate in vitro, an activity manifested in vivo as punctate cytoplasmic aggregates that colocalize vimentin and F-actin. WFA's potent dominant-negative effect on F-actin requires vimentin expression and induces apoptosis. Finally, we show that WFA-induced inhibition of capillary growth in a mouse model of corneal neovascularization is compromised in vimentin-deficient mice. These findings identify WFA as a chemical genetic probe of IF functions, and illuminate a potential molecular target for withanolidebased therapeutics for treating angioproliferative and malignant diseases.
INTRODUCTION
In the postgenomic era, natural products are gaining importance in cell biological applications as molecular probes of protein function [1] , expanding from their more traditional role as chemical scaffolds for drug development. Particularly interesting to molecular medicine are the pharmacologically active small molecules, the newly discovered binding targets of which can offer critical molecular insight into the drugable chemical space of the human proteome [2] . Such bioactive small-molecule tools can also become molecular beacons of target functions, a feature that has applications in target-based disease diagnosis and patient responses to drug therapies.
Angiogenesis, which is the growth of new blood vessels from preexisting vasculature, occurs widely in numerous human pathologies, including cancers, arthritis, endometriosis, age-related macular degeneration, diabetic retinopathy, etc. [3] . As new developments in antiangiogenesis research are providing crucial knowledge of which protein targets are sensitive to drug treatment, there is still the increasing need to discover novel drugable targets [4] . To probe the chemical diversity of plants for new classes of angiogenesis inhibitors, we recently developed a high-density, cell-based screening assay, and focused on the medicinal plant Withania somnifera [5] , because of the elaboration of alkaloids and steroidal lactones (withanolides) present in this plant [6] . W. somnifera has also rich ethnopharmacological uses in traditional East Indian medicine for treatment of arthritis, immunological disorders, and bleeding conditions in women [7] , which suggested to us the presence of inhibitors that target an underlying angiogenic mechanism. The rational screening strategy led to the successful isolation of withaferin A (WFA), an inhibitor known for its potent anticancer activities [8] . We demonstrated that WFA potently blocks angiogenesis in vivo [5] , and investigations on the mode of action of WFA and structurally related congers has revealed that this class of withanolides target the ubiquitin-proteosome pathway (UPP) and cause rapid increases in polyubiquitinated proteins in vascular endothelial cells [5, 9] .
To understand the mode of action of WFA, we exploited the chemical genetic approach to discover the in vivo binding targets of small molecules [10, 11] . To this end, we synthesized a novel WFA-biotin analog, in which the biotin affinity tag was linked to WFA via a long hydrocarbon chain residue [12] , a strategy we and others have employed extensively to afford the successful characterization of small-molecule targets [13] [14] [15] [16] . Using the novel WFAbiotin probe, which maintains the UPP-targeting activity of WFA, we previously showed that a 56 kDa protein is irreversibly targeted by WFA in human umbilical vein endothelial cells (HUVECs) [12] . Here, we have isolated this in vivo binding protein of WFA, and show that it is the type III intermediate filament (IF) protein vimentin. As vimentin is abundantly expressed by mesenchymal cells and plays a critical role in wound healing, angiogenesis, and cancer growth [17] [18] [19] , here we demonstrate that WFA can be used as a chemical genetic probe of vimentin, identifying the dominant-negative role of WFA-modified vimentin as a promoter of cellular apoptosis.
RESULTS AND DISCUSSION

WFA Targets the IF Protein Vimentin
To afford the isolation of the WFA ( Figure 1A ) target, we performed scale-up ligand binding studies employing bovine aortic endothelial cells (BAECs). The WFA-biotin analog (WFA-B; see Figure S1 in the Supplemental Data available with this article online) was incubated with BAECs in the presence and absence of unconjugated WFA, and cell lysates containing newly biotinylated proteins were affinity-purified over NeutrAvidin columns and fractionated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gels stained with (B) Affinity isolation of WFA-B-binding proteins. BAECs were preincubated with DMSO (vehicle) or with 5 mM WFA for 30 min and subsequently with 5 mM WFA-B for 2 hr. Cell lysates prepared in 1% Triton X-100 buffer were purified over NeutrAvidin affinity columns and subjected to SDS-PAGE. The gel was stained with Coomassie blue. The arrow points to the 56 kDa protein band and asterisks mark the coeluted 51 and 43 kDa proteins. (C) WFA-B binds to the 56 kDa protein in HUVECs. Cells were preincubated with DMSO or WFA for 30 min and subsequently with WFA-B for 2 hr. Soluble proteins extracted in 1% Triton X-100 were fractionated by SDS-PAGE and blotted. Blots were developed with Streptavidin-HRP. (D) WFA-B binds vimentin in HUVECs. Cell cultures were preincubated with DMSO (vehicle) or with 5 mM WFA or 1 mM for 30 min and subsequently with 5 mM WFA-B for 2 hr. Cell lysates prepared in 1% Triton X-100 buffer were purified over NeutrAvidin affinity columns and subjected to SDS-PAGE and western blotted with anti-vimentin V9 antibody. The bottom panel represents streptavidin-HRP detection of endogenous biotinylated species used as a loading control. (E) Tetrameric soluble hamster vimentin was incubated with different doses of WFA or inactive congener 12-D WS for 1 hr and subsequently with 0.3 mM WFA-B for 1 hr at 37 C. The proteins were fractionated by SDS-PAGE, blotted and probed with vimentin V9 antibody for loading control, stripped, and reprobed with streptavidin-HRP to detect biotinylated adducts.
Chemistry & Biology
A Binding Target of Withaferin A Coomassie blue dye confirmed the isolation of this 56 kDa protein from BAECs, and revealed that in vivo competition with unconjugated WFA dramatically reduced the levels of this protein ( Figure 1B ). LC-MS/MS characterization of this protein identified the 56 kDa protein as vimentin (27% protein coverage; Figure S2 ), an IF protein that is abundant in mesenchymal cells. To further support that vimentin is bound by WFA-B in vivo, HUVECs were treated with WFA-B in the presence and absence of unconjugated WFA, and total cellular lysates were fractionated by SDS-PAGE and protein blots probed with streptavidin-horseradish peroxidase (HRP). We found that the biotin label is incorporated in this 56 kDa protein in a WFA-competitive manner ( Figure 1C ). Additionally, when such biotinylated proteins from HUVECs were affinity purified over NeutrAvidin columns, WFA treatment competed with the binding of vimentin to the NeutrAvidin column in a doseresponsive manner, as shown by western blot experiments ( Figure 1D ). As prior studies have revealed that the tetrameric form of vimentin is found in vivo and exists in dynamic equilibrium with filament polymers [20] , we therefore investigated whether WFA binds to purified tetrameric vimentin in vitro. We performed ligand binding assays employing unconjugated WFA as a specific competitor and 12-deoxowithastramonolide (12-D WS) as a nonspecific competitor [12] , and show that vimentin is bound by WFA-B in a WFA-competitive manner (Figure 1E) . Interestingly, the WFA-B-affinity chromatographic approach has also led to coisolation of two other proteins of sizes 51 kDa and 43 kDa that were simultaneously reduced in intensity by WFA treatment in BAECs (Figure 1B) . The characterization of these proteins by LC-MS/MS revealed that they are 51 kDa b-tubulin and 43 kDa b-actin ( Figure S3 ). Importantly, these NeutrAvidinbound proteins, when subjected to 6 M urea treatment, caused disruption of b-actin and b-tubulin binding, whereas that of vimentin was not affected ( Figure S4 ), suggesting that the in vivo binding target of WFA-B is vimentin. One possibility is that vimentin, through its interaction with plakins [21] , could bind b-actin and b-tubulin and provide a cargo for microtubule-dependent protein transport [22] , or it may possibly also bind to b-actin via direct interaction [23] . In this respect, we previously found a 180 kDa protein that copurifies with 56 kDa vimentin upon NeutrAvidin chromatography [12] , a species which is possibly the plakin, bullous pemphigoid antigen 1. Clearly, the coisolation of vimentin-associated proteins with WFA-B unveils a novel use for this reagent in chemical proteomics.
WFA Covalently Modifies the Unique Cysteine Residue in Tetrameric Vimentin
Next, to identify the amino acid residue(s) of vimentin modified by WFA, we incubated purified hamster tetrameric vimentin with WFA for 1 hr at 37 C and subjected the protein-ligand complexes to tryptic digestion and LC-MS/MS analysis. A search for the position of adduct formation (a molecular mass shift of 470) in the tryptic fragments of vimentin revealed that the sole cysteine residue at position 327 (position 328 in human vimentin) in the a-helical coil coiled 2B rod domain of vimentin is uniquely modified by WFA (Figure 2 ). This finding is consistent with prior reports that WFA is known to react with protein thiolnucleophiles and can undergo Michael addition through its reactive A-ring ( Figure 1A ) pharmacophores [24] .
Molecular Model of Tetrameric Vimentin Reveals a Novel WFA-Binding Pocket
We then developed a three-dimensional model of the WFA-vimentin complex by using X-ray crystal structures of vimentin [25] and WFA [26] . Molecular modeling studies revealed a stable binding mode for WFA in the surface binding pocket of tetrameric vimentin between the pair of head-to-tail a-helical dimers ( Figure 3A) . In this simulated model, the C3 and C6 carbons of WFA lie in close proximity to the cysteine residue in the vimentin A helix ( Figure 3B ), permitting a nucleophilic attack by this thiol group on the electrophilic carbon centers ( Figure 3C ). Remarkably, the amino acid residues of vimentin (Gln324, Cys328, and Asp 331) that make contact with WFA ( Figure 3C ) are identical from mammals down to ancient fish, such as sharks [27] (Figure S5 ). Another feature illustrated by this model is that the orientation of C27 hydroxyl group places this moiety outside the binding cleft; thus, biotinylated WFA ( Figure S1 ) is able to retain the flexibility to bind immobilized NeutrAvidin after modifying tetrameric vimentin in vivo. On the other hand, the simulated model of vimentin/the inactive congener 12-D WS ( Figure 3D ) reveals that the C5 alpha-hydroxyl and the C6-C7 epoxide of WFA are positioned to prevent rear side nucleophilic attack by the reactive thiol group on 12-D WS. This distinction between these two withanolides in their binding modes with vimentin is further corroborated by comparing the molecular docking-simulated internuclear distances between WFA and 12-D WS with vimentin ( Figure S6 ), and these data are consistent with lack of in vitro binding activity of 12-D WS to vimentin ( Figure 1D ).
Covalent Modification of Tetrameric Vimentin by WFA Causes Formation of Filament Aggregates In Vitro and In Vivo
The clinical importance of the cysteine residue in vimentin lies in its propensity for being preferentially oxidized in vimentin compared to other cytoskeletal proteins from rheumatoid arthritis patients [28] . Because this cysteine residue under oxidizing conditions can participate in disulfide cross-linking between a pair of vimentin dimers, leading to disruption to the filament structure in vitro [29] , we next investigated how chemical modification of cysteine by WFA affects the vimentin IF structure. Employing soluble tetrameric vimentin in filament polymerization assays in vitro, we show that, although WFA at high doses does not block filament assembly per se, the drug induces formation of filamentous aggregates, many of which display amorphous condensed structures, as revealed in negatively stained transmission electron micrographs (Figure 4 ). This phenotype is not observed with lower doses of WFA or equivalent high doses of the inactive congener, 
WFA Causes Vimentin Fragmentation In Vivo
As it became apparent that vimentin targeting by WFA may initiate signaling events leading to cellular apoptosis, we wanted to know whether soluble tetrameric vimentin, which is difficult to differentiate from the abundant filaments by staining, is also affected by WFA. Through western blot analysis of soluble proteins from HUVECs treated Chemistry & Biology with WFA, we show dose-dependent (above 2 mM) increases in vimentin cleavage products ( Figure 5A ), which became more pronounced by 2 hr, paralleling the decreased expression of the 56 kDa form after drug treatment ( Figure 5B ). Since several posttranslationally modified isoforms of vimentin exist in cells, we performed two-dimensional western blot analysis to better characterize the vimentin-targeting activity of WFA. As compared with the vehicle-treated cells ( Figures 5C and 5D ), WFA treatment was found to cause reductions in the levels of several $53-56 kDa isoforms ( Figure 5E ), with WFA-B treatment also inducing similar reduction in levels of vimentin isoforms at cyctotoxic doses of this WFA analog ( Figure 5F ). These data further support the in vivo drugmimetic effect of WFA-B.
The Ubiquitin-Proteasome Pathway-Targeting Activity of WFA is Mediated by Vimentin Since IF protein aggregation has been shown to negatively impact the UPP, resulting in proteasome inhibition [30] , we queried whether the UPP-targeting activity of WFA [5, 9] is also regulated in a vimentin-dependent manner. Employing the widely used MCF-7 vimentin-deficient cell culture model [31] , we found that WFA causes increased levels of polyubiquitinated proteins in vimentin-transfected MCF-7 cells, but only moderately in the vector controls ( Figure 6A ). We addressed the importance of the 2-3 unsaturated position of the A-ring on UPP activity of WFA by structure-activity relationship studies. We found that the semisynthetic analogs, 3b-methoxy-dihydrowithaferin A or 3b-thiophenoxy-dihydrowithaferin A, like the inactive congener, 12-D WS [12] , also failed to increase cellular levels of ubiquitinated species ( Figure S7A ). Similarly, vimentin-transfected MCF-7 cells treated with 12-D WS also failed to increase levels of ubiquitinated proteins ( Figure S7B ). These results are consistent with the binding mode of WFA for vimentin ( Figure 3) . Next, to corroborate that vimentin targeting, and not the possible direct inhibition of the 20S proteasome by WFA, mediates its UPP-targeting function [9] , we tested WFA in proteasome kinetic assays. We show that, whereas the highly selective 20S proteasome inhibitor, epoxomicin [13] , significantly inhibits the 20S proteasome's major catalytic function at 10 nM, WFA minimally inhibits this catalytic activity, even at cytotoxic concentrations of 10 mM ( Figure 6B ).
, a measure of the efficiency of inactivation [13] , was calculated to be 340 ± 80 (0.5-10 mM) for WFA, while that of epoxomicin is 44,510 ± 7,000 (10-75 nM). Contrary to a recent report [32] , our data suggest that WFA-modified vimentin may mediate sequestration of ubiquitinated proteins and result in proteasome inhibition in vivo. Thus, employing cell lines derived from vimentin-deficient and isogenic wild-type mouse strains [33] , we show that vimentin deficiency confers enhanced resistance to WFA-induced apoptosis with wild-type cells having a 7-fold higher rate of apoptosis, whereas 12-D WS does not induce apoptosis in wild-type cells ( Figure 6C) . Furthermore, exploiting a protein transduction methodology to introduce the WFA-modified, dominant-negative vimentin tetramers into cells, we found by immunostaining that endogenous vimentin IFs and F-actin are found to aggregate, whereas cells transduced with vehicle-treated vimentin do not produce this phenotype ( Figure 6 ; compare Figures 6D and 6F) . Thus, vimentin targeting by WFA has a dominant-negative affect on the cystosketon architecture, as seen by staining for F-actin ( Figures 6E  and 6G ). Collectively, these findings identify a potent cytoskeleton-perturbing activity of WFA, which is mediated by vimentin.
The In Vivo Antiangiogenic Activity of WFA is Mediated by Vimentin We previously reported that WFA exhibits potent angiogenesis inhibitory activity in vivo [5] . Thus, here we have investigated whether the pharmacological activity of WFA on de novo capillary growth is altered by vimentin deficiency. Through the use of the mouse model of injuryinduced corneal neovascularization, we found that WFA markedly suppressed neovascularization in wild-type mice (73% inhibition; n = 8; p = 0.002), whereas it only marginally attenuated neovascularization in vimentin-null mice (29% inhibition; n = 10; p = 0.005) (Figure 7 ), revealing that inhibition of capillary growth by WFA is largely mediated by vimentin. It is likely that vimentin in corneoscleral capillaries and fibroblastic cells of the injured corneal stroma [34] is targeted by WFA in this angiogenesis model. Furthermore, in accord with our in vitro studies, we find that the inactive congener, 12-D WS, does not alter corneal neovascularization in wild-type Svev mice (<1% activation; n = 6; p = 0.1724). Interestingly, the vascularization response of vimentin-deficient mice is not as extensive as in wild-type mice, which is consistent with previous reports on impaired angiogenesis in vimentin deficiency [19] and the likely impairment of vimentin-dependent mechanosignaling events in the vasculature [35] . WFA has recently been reported to bind annexin II in cancer cell lines [36] . However, this 36 kDa protein is not detected in affinity-purified proteins from bovine ( Figure 1B ) or human ( Figure 1C ) [12] endothelial cells, nor was it detected by western blotting of NeutrAvidinpurified proteins in our studies (data not shown). Thus, we are drawn to the interpretation that differences in the construction of the biotinylated WFA analogs (e.g., inclusion of a long, linear hydrocarbon linker between the natural product and biotin) [10, 37] or their applications for target isolation (in vitro versus in vivo labeling) could account for different targets being bound to WFA. It is also possible that WFA has binding specificities for different targets in vivo, which may also be context related. Since vimentin deficiency does not abrogate WFA's biological activities totally, the existence of other relevant targets of this compound must be considered. The related IF protein, desmin, Chemistry & Biology could be a relevant target, because the WFA-binding motif is conserved in desmin ( Figure S5 ) [27] . Thus, the modest WFA inhibitory activity on corneal neovascularization in vimentin-deficient mice may be due to the targeting of desmin in mural cells of invasive capillaries [34] . While this theory remains to be tested, our findings underscore the importance of multiple target activity of WFA that could be exploited for drug development.
In conclusion, this study illustrates the cell biological and pharmacological use of a small molecule that targets type III IF proteins via modification of the conserved rod 2B domain. Intriguingly, a recent report has shown that the antiangiogenic and chemopreventive agent, epigallocatechin gallate, also binds to vimentin, although via the Nterminal region of this protein [38] . The revelation that vimentin is a critical target of such chemically diverse natural products (withanolides and flavanoids) provides new opportunities to investigate potential synergistic effects of these inhibitors on cell signaling networks evoked under malignant, angiofibrotic, and inflammatory conditions [39] .
SIGNIFICANCE
Withaferin A (WFA) is a prototype of the withanolide class of natural products that exhibit diverse pharmacological activities, including antitumor, antiangiogenic, cardioprotective, anti-inflammatory, and immunomodulatory effects [7] . Our findings showing that site-specific modification of vimentin by WFA in vivo causes endothelial cell apoptosis illuminates the chemical genetic approach of perturbing the conserved rod 2B domain to produce a dominant-negative effect on intermediate filament (IF) protein function. Use of such a small molecule to alter IF function can serve as a complementary approach to classical genetic studies of disorders of IFs [40] , and, potentially, WFA-B can also be exploited as a chemical proteomic reagent for investigating the IF proteome. Thus, WFA and derivative steroidal lactones represent a class of useful chemical genetic tools for studies of the type III IF proteins. As vimentin modulates the immune response [41] , and is overexpressed in prostate and other cancers [42] , WFA holds great promise as a potential drug lead for the development of small-molecule therapeutics.
EXPERIMENTAL PROCEDURES
All cell culture supplies were purchased from GIBCO, unless otherwise specified. Antibodies were from Santa Cruz Biotechnology, unless otherwise specified. WFA and 12-D WS were obtained from Chromadex, and stock solutions were freshly prepared in DMSO. The synthesis of WFA analogs, 3b-methoxy-dihydrowithaferin A and 3b-thiophenoxy-dihydrowithaferin A, is described in Supplemental Experimental Procedures provided in the Supplemental Data. All cell reagents were purchased from Invitrogen. ) and MFT-6 cells from embryo fibroblasts of wild-type (Vim +/+ ) mice were obtained from Robert Evans (University of Colorado, Denver, CO) and cultured in F12:DMEM (1:1) medium supplemented with 5% FBS. All cells were cultured in humidified incubators at 37 C-5% CO 2 conditions.
Cell Cultures and Reagents
Isolation of WFA-B-Binding Proteins by Affinity Chromatography
The synthesis and chemical characterization of WFA-B and its use to identify biotinylated proteins from HUVECs was previously reported [12] . For scale-up studies, BAECs were preincubated with DMSO or 5 mM WFA for 1 hr and subsequently treated with 5 mM WFA-B for 2 hr. Cells were washed in ice-cold phosphate-buffered saline (PBS) and cytoplasmic extracts were prepared in buffer A (5 mM Tris, pH 7.6, 50 mM NaF, 1% Triton X-100, 5 mM EGTA) supplemented with a proteinase inhibitor cocktail (Roche). After centrifugation, equal amounts of protein were precleared on agarose beads (Sigma) to remove nonspecific agarose-binding proteins. The beads were centrifuged and precleared cell lysates were repeatedly loaded three times on columns containing NeutrAvidin-agarose beads (Pierce) to maximize immobilization of biotinylated proteins. After extensive washing with ice-cold buffer A, bound biotinylated proteins were eluted in Laemeli gel loading buffer containing b-mercaptoethanol, and fractioned by SDS-PAGE on 15 3 15 cm gels. Gels were stained with Coomassie blue dye, and bands corresponding to 56 kDa, 51 kDa, and 43 kDa protein were excised for mass spectrometric analysis.
Identification of Affinity-Purified Proteins by LC-MS/MS
All mass spectra reported in this study were acquired by the University of Kentucky Mass Spectrometry Facility. Gel pieces were digested with trypsin, and LC-MS/MS spectra were acquired on a ThermoFinnigan LCQ ''Classic'' quadrupole ion trap mass spectrometer (Finnigan Co., San Jose, CA). Separations were performed with an HP 1100 high-performance liquid chromatograph modified with a custom splitter to deliver 4 ml/min to a custom C18 capillary column (300 mm inner diameter 3 15 cm). Gradient separations consisted of a 2 min isocratic step at 95% water and 5% acetonitrile (both phases containing 0.1% formic acid). The organic phase was increased to 20% acetonitrile over 8 min, and then increased to 90% acetonitrile over 25 min, held at 90% acetonitrile for 8 min, and then increased to 95% in 2 min; finally, they were returned to the initial conditions in 10 min (total acquisition time, 45 min with a 10 min recycle time). Tandem mass spectra were acquired in a data-dependent manner. Three microscans were averaged to generate the data-dependent full-scan spectrum. The most intense Chemistry & Biology ion was subjected to tandem mass spectrometry, and three microscans were averaged to produce the MS/MS spectrum. Masses subjected to the MS/MS scan were placed on an exclusion list for 2 min. Resulting MS/MS spectra were searched against mammalian proteins in the Swiss-Prot database with the Mascot search engine (Matrix Science).
WFA Binding Site Identification in Vimentin
Hamster tetrameric vimentin (0.5 mg/ml) was incubated with 10 mM WFA or an equivalent amount of DMSO for 1 hr at 37 C. Protein-ligand complexes were subjected to tryptic digestion and LC-MS/MS analysis. The assignment of fragment ions in the MS/MS of the modified and unmodified peptides was obtained with the SEQUEST software tool ''FuzzyIons'' (distributed by ThermoFinnigan) to annotate the spectra from WFA-treated and DMSO-treated samples. This analysis verifies both the peptide amino acid sequence and the location and mass of the modification (+470 daltons on cysteine).
3D Model of the Human Vimentin Fragment
The initial coordinates of 2B human vimentin fragment used in our computational studies came from the X-ray crystal structure (Protein Data Bank [PDB] code: 1gk4) [25] deposited in the PDB. To encompass the structure of the protein environment surrounding the active residue Cys328, the missing residues of the 2A fragment (i.e., residues 313-327 in A and B helices) were built with the a-helical template structure and the automated homology modeling tool, Modeler/InsightII software (Accelrys, Inc.). Then, the best 3D model was solvated in water and refined by performing a long-time molecular dynamics (MD) simulation in water (see Supplemental Experimental Procedures).
Molecular Docking
To explore the possible vimentin-ligand binding mode, the first step was to dock the ligand (i.e., WFA) or 12-D WS to vimentin tetramer fragment by virtue of their geometric complementarity. We aimed to find where the ligand could be inserted most comfortably. The molecular docking for each vimentin-ligand binding was carried out in the same way as we recently did for studying other protein-ligand binding systems [43] . Briefly, a ligand-binding site was defined as that consisting of the residues within a sphere (with a radius of 20 Å ) centered at Cys328 residue. The ligand was initially positioned at $10 Å in front of Cys328 of the binding site. The initial docking calculations were performed on the ligand with the vimentin fragment binding site by the ''automatic docking'' Affinity module of the InsightII package (Accelrys, Inc.). The Affinity methodology uses a combination of Monte Carlotype and simulated annealing procedures to dock the guest molecule (the ligand) to the host (the receptor). The vimentin-ligand binding structure obtained from the initial docking was further refined by performing an MD simulation in a water bath (see Supplemental Experimental Procedures).
Western Blotting Experiments
After treatments, cells were washed in PBS and extracts having equal amount of proteins were subjected to SDS-PAGE on 4%-20% Trisglycine gels (BioEpress) and transferred to Immun-Blot PVDF membrane (Bio-Rad) by standard techniques. Primary antibodies were diluted in 5% nonfat dry milk Tris-buffered saline, 0.02% Tween-20 (NFDM-TBST) at the concentration of 1:500, and secondary antibodies were used at 1:1000 dilution. Blots were extensively washed in TBST buffer and developed by enhanced chemiluminescence method (Amersham) and exposed to X-ray film.
Analysis of Vimentin Isoforms by 2D Gel Electrophoresis
HUVECs cultured in 60 mm dishes were treated with vehicle or 5 mM WFA or 20 mM WFA-B for 2 hr. Cells were washed in ice-cold PBS and collected in buffer A. After centrifugation at 14,000 3 g for 10 min, equal amounts of protein from supernatants were suspended in 8 M urea, 50 mM dithiothreitol (DTT), and 0.2% Bio-lite ampholytes pH 3-5 and pH 5-8 (2:1 ratio; Biorad) with 0.01% bromophenol blue.
The protein lysate was centrifuged at 14,000 3 g for 5 min to precipitate insoluble material before incubation with 11 cm IPG strips (pH 4-7; Biorad). Gels were actively rehydrated at 50 mA for 12 hr with a Protean IEF cell system (Biorad). Isoelectric focusing was subsequently conducted for 5.5 hr (250 V for 20 min, 8,000 V for 2.5 hr, and 8,000 V for 25,000 V hr). Strips were dipped in equilibration buffer 1 containing 6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glycerol, and 2% (w/v) DTT for 10 min, followed by an incubation in equilibration buffer 2 containing 6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glycerol, and 2.5% (w/v) iodoacetamide for 10 min. Strips were laid on second dimension 4%-20% gradient gels (Biorad) and run at 200 V for 1 hr. Proteins were transferred at 100 V for 45 min for western blotting. The range of inhibitor concentrations tested was chosen so that several half-lives could be observed during the course of the measurement. Reactions were performed with inhibitor concentrations that were < 100-fold of those of the proteasome assayed.
Corneal Neovascularization Assays in Mouse
All animal experiments were conducted in accordance with the Declaration of Helsinki, and procedures approved by IACUC committee of the University of Kentucky. Mice were housed in specific pathogenfree cages in designated lab animal housing facilities. Vimentin homozygous-deficient mice (Vim
À/À
) and mice that were vimentin-heterozygous deficient (Vim +/À ) in the 129/Svev background were obtained from David Markovitz (University of Michigan Medical Center) and breeding colonies established at the University of Kentucky. Agematched littermates were genotyped by polymerase chain reaction, as previously described [44] , and Vim À/À and Vim +/+ mice were employed for corneal vascularization experiments [45] . In brief, mice between 4 and 6 wk of age were anesthetized by intraperiteoneal (i.p.) injection of ketamine and xylazine. Corneas were topically anesthetized by application of proparacain eye drop, and 1 ml drop of dilute 0.15 M sodium hydroxide was applied for 1 min. The cornea was immediately washed extensively in saline solution, and corneal and limbal epithelium gently removed by scraping with a blunt Tooke corneal knife. The cornea was topically treated with atropine eye drop and covered with tobramycin and erythromycin antibiotic eye ointment. WFA or 12-D WS (2 mg/kg solubilized in DMSO) or vehicle (DMSO) was injected i.p. in respective drug or control groups of mice after their recovery from corneal injury, and subsequently every day thereafter for a period of 10 days. Mice were humanely killed and eyes enucleated. The anterior segment half of eyes were dissected and corneal buttons were prepared. Corneal tissues were fixed in 100% acetone for 20 min, washed in PBS for 1 hr, and blocked for 18 hr in 1% BSA-PBS at 4 C.
Cornea whole-mount staining was performed by incubating tissues in FITC-conjugated rat anti-mouse CD31 antibody (BD PharMingen; 1:333 dilution in 1% BSA-PBS) for 12 hr, washed away for 24 hr at 4 C in 1% BSA-PBS, and affixed to glass slides with a coverslip. Fluorescent staining was visualized on a Nikon TE2000 microscope, and quantified by importing digital images to NIH ImageJ [45] .
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